Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib.
Transl Lung Cancer Res 2020;9(5):2188 2190 http:/dx.doi.org/10.21037/tlcr 20 847 A case study of a patient with EGFR G724S who responded to afatinib monotherapy after disease progression on osimertinib was reported before (1) Incidentally, we encountered a patient who also had EGFR G724S who developed meningeal metastases. After treatment with a regimen of osimertinib combined with afatinib, our patient achieved significant clinical benefits. A 49 year old Chinese male smoker was found to have a pulmonary mass in the right middle lobe by chest computed tomography (CT) scan during a health checkup on October 25, 2016. The patient underwent positron emission tomography computed tomography (PET CT) on November 01, 2016 (Figure 1A) which showed irregular soft tissue nodules in the right middle lobe (measuring approximately 2.1 cm x 2.4 cm) lymph node metastasis in the right hilar and mediastinum (3A, 4R, 10R, and 7 areas) and multiple bone metastases. On November 07, 2016, the patient underwent thoracoscopy lung wedge resection and pleural biopsy. During the operation, extensive pleural cavity implantation and metastases were observed. Postoperative pathology and next generation sequencing (NGS) led to the diagnosis of lung adenocarcinoma with an EGFR exon 19 deletion mutation (EGFR 19del) Subsequently, the patient started gefitinib 250 mg daily as first line therapy on November 25, 2016, and achieved partial response (PR) On December 14, 2017, craniocerebral magnetic resonance imaging (MRI) showed multiple progressive small metastases in the brain (Figure 1B) Consequently, the patient's regimen was changed to osimertinib 80 mg daily from December 15, 2017. On November 19, 2018, the patient experienced an increase in pleural effusion as disease progression. An NGS test of the patient's pleural effusion revealed the emergence of EGFR G724S with pre existing EGFR 19del. Thereafter, while maintaining the use of osimertinib, the patient received chemotherapy including carboplatin and pemetrexed, with bevacizumab as an antiangiogenic therapy. After experiencing dizziness and headache, the patient was reexamined by craniocerebral MRI on August 05, 2019, which revealed extensive abnormal thickening and enhancement of the meninges; meningeal metastases were considered. CT at the same time showed multiple liver metastases and peritoneal metastases. Another NGS examination of the patient's pleural effusion and blood was performed, which showed EGFR G724S and 19del mutation were still present in both samples. Considering both in vitro and in vivo studies have indicated that EGFR G724S/19del can induce resistance to osimertinib in patients while maintaining sensitivity to afatinib (2,3) the patient began afatinib 40 mg daily while continuing osimertinib 80 mg daily on August 06, 2019. After 1 month, the patient's neurological symptoms were significantly relieved, and after 2 months, follow up CT and MRI showed that the patient's meningeal metastases, liver metastases and peritoneal metastases were significantly reduced (Figure 1C,D) To date (March 26, 2020, the cutoff day) the patient has continued to receive afatinib in combination with osimertinib, and no obvious adverse reactions have been observed (Figure 1E) All procedures performed in studies involving human participants were in Letter to the Editor
Translational lung cancer research